Literature DB >> 29682998

Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Alexander Panickacheril John1, Elvin Kay Fon Ko2, Arun Dominic3.   

Abstract

Entities:  

Keywords:  clozapine; clozapine initiation; prescription; treatment-resistant schizophrenia

Mesh：

Substances：

Year:  2018        PMID： 29682998      PMCID： PMC6099752          DOI： 10.1177/0706743718772522

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN： 0706-7437            Impact factor:   4.356


× No keyword cloud information.
  48 in total

1.  Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved?

Authors:  Jan P A M Bogers; Peter F J Schulte; Daniel Van Dijk; Bert Bakker; Dan Cohen
Journal:  J Clin Psychopharmacol       Date:  2016-04       Impact factor: 3.153

2.  Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians.

Authors:  Kay Hodge; Sean Jespersen
Journal:  Int J Ment Health Nurs       Date:  2008-02       Impact factor: 3.503

3.  An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.

Authors:  Ofer Agid; Tamara Arenovich; Gautam Sajeev; Robert B Zipursky; Shitij Kapur; George Foussias; Gary Remington
Journal:  J Clin Psychiatry       Date:  2011-03-08       Impact factor: 4.384

4.  Clozapine Use in First-Episode Psychosis: The Singapore Early Psychosis Intervention Programme (EPIP) Perspective.

Authors:  Charmaine Tang; Mythily Subramaniam; Boon Tat Ng; Edimansyah Abdin; Lye Yin Poon; Swapna K Verma
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

5.  Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study.

Authors:  Jimmi Nielsen; Rene Ernst Nielsen; Christoph U Correll
Journal:  J Clin Psychopharmacol       Date:  2012-10       Impact factor: 3.153

Review 6.  Implementation of treatment guidelines for specialist mental health care.

Authors:  Irene Bighelli; Giovanni Ostuzzi; Francesca Girlanda; Andrea Cipriani; Thomas Becker; Markus Koesters; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

7.  Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine.

Authors:  Jessica L Gören; Adam J Rose; Ryann L Engle; Eric G Smith; Melissa L D Christopher; Nathaniel M Rickles; Todd P Semla; Megan B McCullough
Journal:  Psychiatr Serv       Date:  2016-06-15       Impact factor: 3.084

8.  Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia.

Authors:  Alp Üçok; Uğur Çikrikçili; Sercan Karabulut; Ada Salaj; Meliha Öztürk; Öznur Tabak; Rümeysa Durak
Journal:  Int Clin Psychopharmacol       Date:  2015-09       Impact factor: 1.659

9.  Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.

Authors:  Amanda J Wheeler
Journal:  Ann Pharmacother       Date:  2008-05-13       Impact factor: 3.154

10.  Clozapine Use in a Cohort of First-Episode Psychosis.

Authors:  Roisin Doyle; Caragh Behan; Donal OʼKeeffe; Sarah Masterson; Anthony Kinsella; Aine Kelly; Ann Sheridan; Dolores Keating; Caroline Hynes; Kevin Madigan; Elizabeth Lawlor; Mary Clarke
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153
View more
  5 in total

1.  Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces.

Authors:  Evyn Peters; Arash Shamloo; Rohit J Lodhi; Gene Marcoux; Kylie Jackson; Shawn Halayka; Lloyd Balbuena
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

2.  Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Authors:  C Okhuijsen-Pfeifer; M Z van der Horst; C A Bousman; B Lin; K R van Eijk; S Ripke; Y Ayhan; M O Babaoglu; M Bak; W Alink; H van Beek; E Beld; A Bouhuis; M Edlinger; I M Erdogan; A Ertuğrul; G Yoca; I P Everall; T Görlitz; K P Grootens; S Gutwinski; T Hallikainen; E Jeger-Land; M de Koning; M Lähteenvuo; S E Legge; S Leucht; C Morgenroth; A Müderrisoğlu; A Narang; C Pantelis; A F Pardiñas; T Oviedo-Salcedo; J Schneider-Thoma; S Schreiter; E Repo-Tiihonen; H Tuppurainen; M Veereschild; S Veerman; M de Vos; E Wagner; D Cohen; J P A M Bogers; J T R Walters; A E Anil Yağcıoğlu; J Tiihonen; A Hasan; J J Luykx
Journal:  Transl Psychiatry       Date:  2022-04-07       Impact factor: 7.989

3.  Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.

Authors:  Farhana Islam; Daniel Hain; David Lewis; Rebecca Law; Lisa C Brown; Julie-Anne Tanner; Daniel J Müller
Journal:  Pharmacogenomics J       Date:  2022-06-16       Impact factor: 3.245

4.  A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach.

Authors:  Mattia Veronese; Barbara Santangelo; Sameer Jauhar; Enrico D'Ambrosio; Arsime Demjaha; Hugh Salimbeni; Jin Huajie; Paul McCrone; Federico Turkheimer; Oliver Howes
Journal:  Neuropsychopharmacology       Date:  2020-09-22       Impact factor: 7.853

5.  Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile.

Authors:  Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-01       Impact factor: 2.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.